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The causes of ARF in hospitalised HIV-infected patients may 
be community- or hospital-acquired. The latter group is 5 - 
10 times more common, with worse outcomes.4 The known 
causes of ARF are similar to non-HIV patients, with the most 
common being acute tubular necrosis (ATN) secondary to 
sepsis, hypotension, dehydration and nephrotoxins (Table 
I).3-6 Although potentially reversible with appropriate 
medical therapy and dialysis, ARF carries a high mortality 
in this population.5 Biopsy studies have confirmed a 
wide range of aetiologies.5,7,8 In one study of hospitalised 
patients with HIV infection, ARF occurred in up to 20% of 
cases.2 In another study, the short-term prognosis in this 
group of patients showed 18% mortality at 2 months, 
with 80% of patients diagnosed with AIDS at the time 
of hospital admission.9 Since the advent of antiretroviral 
therapy (ART), a recent prospective study on ARF in 
ambulatory HIV-infected outpatients with access 
to ART concluded that more severe immuno- 
suppression (CD4 <200/µl and/or HIV-1 RNA level 
>10 000 copies/ml) is the predominant risk factor for ARF.10
Numerous electrolyte and acid-base abnormalities have 
been documented with HIV infection (Table II). Abnormalities 
may arise either from HIV infection, opportunistic 
infections and malignancies associated with advanced 
immunosuppression, or with the many drugs that are used 
to treat HIV-1 and its complications.
The first series of autopsy reports to confirm renal 
disease in HIV-infected patients with clinically advanced 
disease showed a broad spectrum of lesions that include 
ATN, interstitial nephritis, nephrocalcinosis, minimal 
change, mesangial proliferation/hyperplasia and focal 
glomerulosclerosis (FGS).14-17 Reports then began to appear 
in the literature describing various glomerulopathies, 
the most common of which was FGS. The distinguishing 
feature of the ‘classic’ glomerular lesion in HIV was 
collapse of the glomerular tuft – so-called ‘collapsing 
glomerulopathy’.5,7,14,18 Potential mechanisms of glomerular 
injury in HIV are depicted in Table III.
The wide spectrum of glomerulopathies with HIV infection, 
based on biopsy studies, can be categorised as follows:3,19
1. HIV-FGS (‘classic’ HIVAN)
2.  HIV-IC: This group may have hepatitis B or C co-infection. 
The following patterns have been described:
    Mesangial proliferative
    Membranoproliferative (type I and III), lupus-like
    Exudative-proliferative and crescentic IgA
    Membranous
3.  Various glomerulonephropathies: This is a heterogeneous 
group with different aetiologies:
    Minimal change
    Immunotactoid
    Amyloidosis
     Co-morbid disease: Diabetic nephropathy, hypertensive 
nephrosclerosis
4. HIV-TTP/HUS
European and American-based biopsy studies reveal varying 
frequencies of the different histological patterns described 
above where HIVAN is by far the most common. There have 
been studies documenting patterns of renal involvement in 
South Africa. A predominantly outpatient screening study 
was conducted at King Edward Hospital in Durban which 
is only one of a handful of studies that have evaluated the 
prevalence (and significance) of microalbuminuria in the 
HIV-infected population, as a marker of early renal disease. 
Thirty renal biopsies were performed (7 for persistent 
microalbuminuria, 23 for overt proteinuria); biopsy results 
appear in Table IV.20 A study of inpatients at Chris Hani 
Baragwanath Hospital showed that HIV-IC was relatively 
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There is a wide clinical spectrum of renal disease in the course of HIV infection, which includes potentially reversible 
acute renal failure (ARF) (more recently known as acute kidney injury), electrolyte and acid-base disturbances, and 
intrinsic renal disease unrelated to HIV itself (e.g. co-morbid diabetes mellitus and hypertension).1,2 In addition, there is 
the group of HIV-associated glomerulonephropathies that may present with acute or chronic renal failure. Histologically, 
this group is divided into the ‘classic’ HIV-associated nephropathy (HIVAN) with focal segmental glomerulosclerosis 
(HIV-FGS), HIV-associated immune complex disease (HIV-IC), and HIV-associated thrombotic thrombocytopenic purpura/
haemolytic uraemic syndrome (HIV-TTP/HUS).3 It is this group that is primarily implicated in the burden of chronic kidney 
disease (CKD) in the HIV-infected population.
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more common (21%), with HIVAN comprising 27% of 
biopsies (Table IV).21 This contrasted with the histological 
patterns from black populations in the USA, where up to 
60% of renal biopsies show HIVAN. When comparing the 
data from the Chris Hani Baragwanath and King Edward 
hospital cohorts, the data for those with overt proteinuria 
from Durban (there were no patients with microalbuminuria 
in the Chris Hani Baragwanath cohort) are contradictory. 
Possible explanations may be population demographics: the 
Chris Hani cohort comprised symptomatic inpatients with 
advanced renal failure, many of whom required dialysis. 
This was in contrast to the King Edward cohort where most 
of those screened were outpatients with relatively normal 
renal function, presumed to be at earlier stages of renal 
disease.
Very few data exist on screening asymptomatic HIV-
infected patients for early renal disease, especially in Africa. 
In a Kenyan study, 216 antiretroviral-naïve patients were 
screened for renal disease, with an average CD4 count of 
383 cells/µl.22 Twenty-five per cent had creatinine clearance 
(Cr Cl) <90 ml/min, 2% had Cr Cl <60 ml/min, and 8% had 
proteinuria of >1 gram/day. A Ugandan study involved 
229 patients with World Health Organization (WHO) 
clinical stage 3 disease, and CD4 counts were not done; 
they showed a startling prevalence of renal disease, with 
a Cr Cl of <80 ml/min in 48.5% of patients.23 Screening 
showed that 20% had proteinuria >100 mg/dl, and 44.1% 
had leucocyturia on microscopy, suggestive of infection, 
but confirmatory cultures were not done.23 Biopsies were 
not done in either study to confirm the cause of renal 
dysfunction or proteinuria.
The significance of microalbuminuria in HIV-1-infected 
patients is as yet undefined. A recent study showed a 
five-fold increase in the prevalence of microalbuminuria 
in HIV-infected individuals compared with HIV-negative 
controls.24 Microalbuminuria was associated with lower CD4 
counts, and the microalbuminuric group had an increased 
association with known cardiovascular risk factors: insulin 
resistance, systolic hypertension, and a family history of 
hypertension. Whether this translates into an increased 
risk of cardiovascular and renal disease remains to be 
determined.
The numerous glomerular lesions seen in HIV-1 infection 
underlie the importance of renal biopsy in the management 
of HIV-1-infected patients with renal disease. Evidence 
from numerous small studies and case reports has shown 
that pharmacological interventions for HIVAN (less so for 
other glomerular lesions) delay the progression or, in some 
cases, induce reversal of renal disease.25-28
An association between HIV and renal disease was first 
reported in 1984 by investigators in New York City and 
Miami.15,29,30 These groups described HIV-infected individuals 
with nephrotic-range proteinuria and progression to end-
stage renal disease (ESRD) within 8 - 16 weeks. Mortality 
in these patients approached 100% within 6 months of 
diagnosis. During the next several years, the existence of a 
specific HIV-associated nephropathy (HIVAN) was confirmed 
as a distinct clinicopathological entity.16,31-33 HIVAN was 
initially thought to be associated with AIDS but it was later 
Pre-renal
Haemodynamic compromise from hypovolaemia (most commonly dehydration), sepsis, liver failure, heart failure, pancreatitis, non-
steroidal anti-inflammatory agents (NSAIDs)
Intrarenal
n  Acute tubular necrosis (ATN)
Sepsis, ischaemia, toxins (including traditional medication), rhabdomyolysis, hypotension, amphotericin B, pentamidine, aminogly-
cosides, tenofovir, NSAIDs, chemotherapy, radio contrast media
n  Renal infection
Bacteria: micro/abscesses, pyelonephritis, mycoplasma, nocardia
Mycobacteria: tuberculosis and mycobacteria other than tuberculosis
Viruses: herpes, cytomegalovirus, varicella zoster virus, parvovirus
Fungi: aspergillus, cryptococcus, histoplasma, candida, mucormycosis
Parasites: pneumocystis, toxoplasma, microsporidia
n  Glomerulopathies
HIV-associated nephropathy (HIVAN)/HIV-associated immune complex disease (HIV-IC)*
Other glomerulopathies: e.g. IgA, acute post-infectious glomerulonephritis (GN), lupus nephritis, crescentic glomerulonephritis 
(rifampicin)†
Haemolytic uraemic syndrome/thrombotic microangiopathy (HUS/TTP)
Rhabdomyolysis
n  Acute interstitial nephritis
NSAIDs, rifampicin, indinavir, trimethoprim-sulphamethoxazole, atazanavir, immune restoration inflammatory syndrome (IRIS)‡
n  Tumours
Renal cell carcinoma, multiple myeloma, lymphoma, Kaposi's sarcoma
Post-renal
Obstruction – crystalluria from high-dose trimethoprim-sulphamethoxazole or acyclovir, nephrolithiasis due to indinavir/atazanavir, 
herpes-related neurogenic bladder, hyperuricosuria from chemotherapy for haematological malignancies, retroperitoneal fibrosis
*Both HIVAN and HIV-IC are considered part of chronic renal disease but may present as a component of ARF if patients develop acute-on-chronic renal failure. 
†Isolated case report of crescentic glomerulonephritis with rifampicin for TB.11
‡Isolated case reports of acute renal failure with tuberculous immune reconstitution syndrome which showed acute interstitial nephritis on histology.12
TABLE I. COMMON CAUSES (BOTH HIV- AND NON-HIV-RELATED) OF ARF IN THE HIV-INFECTED PATIENT
HIV-ASSOCIATED NEPHROPATHY (HIVAN)
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recognised that the lesion can occur at any stage of HIV 
infection, even prior to antibody seroconversion.34 Most of 
the literature report that patients with HIVAN present late 
in the course of their HIV infection with advanced renal 
failure. This late detection of HIVAN could be the result of 
a lack of screening HIV-infected patients for proteinuria 
and/or renal dysfunction. The relative absence of peripheral 
oedema and hypertension in those with HIVAN may also 
delay diagnosis. The outcome of patients with HIVAN has 
been correlated with the clinical stage of their disease, 
suggesting that survival improves with earlier detection.35 
Regarding the significance of renal dysfunction and 
proteinuria in the HIV-infected population, studies have 
shown an increased relative risk of 2.5 - 3.0 for overall 
mortality, after correcting for other risk factors.36,37 Of 
interest in one study was that 77% of renal abnormalities 
developed with CD4 counts above 200 cells/µl.37 This was 
also seen in the study from Durban where the mean CD4 
count of those with biopsy-proven HIVAN was 232 cells/
µl.3,20 Symptomatic HIVAN is now classified as clinical stage 
4 disease by the WHO.38
There is a marked racial predilection for the development 
of HIVAN – over 90% of patients are black.1,14,35,39-41 This has 
been confirmed in paediatric studies.33 Studies from African 
countries regarding the susceptibility of Africans to HIVAN 
are scanty. The reasons for the racial predilection of HIVAN are 
Electrolyte complications of drugs used to treat HIV/AIDS and common complications 
   Hypernatraemia: rifampicin, amphotericin B, foscarnet
   Hyperkalaemia: ketoconazole, trimethoprim
   Hypokalaemia: rifampicin, amphotericin B, didanosine, foscarnet, tenofovir
   Hypomagnesaemia: mphotericin B, pentamidine
   Hypocalcaemia: didanosine, pentamidine, foscarnet
   Hypouricaemia: rifampicin, tenofovir
   Hyperuricaemia: didanosine, pyrazinamide, ethambutol
    Renal tubular acidosis: amphotericin B, trimethoprim, rifampicin, nucleotide-reverse transcriptase inhibitors (NRTIs), foscarnet, 
cidofovir, Fanconi syndrome with tenofovir
Sodium disorders
   Low sodium (most significant)*
    Hypovolaemia, renal tubular salt-wasting, adrenal insufficiency, syndrome of inappropriate ADH secretion (SIADH), haemodilution 
– usually owing to replacement with inappropriate fluids
Potassium disorders
   Low potassium
   Gastrointestinal losses: by far the most common cause
   Renal losses: drugs: amphotericin B, Fanconi syndrome with tenofovir
   High potassium
   Adrenal insufficiency, acute or chronic kidney disease with tubular damage, drugs (commonly, co-trimoxazole)
Acid-base disorders
   Normal anion gap metabolic acidosis
   Diarrhoea, adrenal insufficiency, renal tubular acidosis (amphotericin B, tenofovir)
   Raised anion gap metabolic acidosis
    Type A lactic acidosis (more common than type B): tissue hypoxia most commonly from protracted hypotension and/or hypovol-
aemia, sepsis, diabetic keto-acidosis
    Type B lactic acidosis: drug-induced mitochondrial toxicity due to zidovudine, didanosine, lamivudine, stavudine, zalcitabine
*Hyponatraemia is relatively common in both HIV-infected in- and outpatients. In hospitalised HIV-infected patients, hyponatraemia has been associated with advanced 
immunosuppression and increased mortality.13
TABLE II. ELECTROLYTE AND ACID-BASE DISORDERS ASSOCIATED WITH HIV-1 INFECTION AND ITS TREATMENT
n  Circulating immune complexes involving:
    Viral antigens and host antiviral antibodies
    Endogenous antigens modified by viral injury and host auto-antibodies
n  In situ immune-mediated mechanisms involving:
    Viral antigens bound to glomerular structures
n  Expression of viral proteins or pathogenic pro-inflammatory factors in tissue inducing the following reactions:
    Cell death through necrosis/apoptosis/cellular dysfunction
    Increased matrix synthesis and/or decreased matrix degradation
    Release of cytokines, chemokines, adhesion molecules, growth factors
n  Direct cytopathogenic effect on glomerular cells with undefined mechanisms
n  Tubulointerstitial injuries due to direct cytopathogenic effects, and secondary mediators released in response to 
glomerular inflammation
n  Haemodynamic disturbance, multiorgan failure
n  Complicating rhabdomyolysis, hepatorenal syndrome
n  Nephrotoxicity of antiviral therapy (occasional)
TABLE III. MECHANISMS OF GLOMERULAR INJURY INDUCED BY HIV INFECTION
EPIDEMIOLOGY AND RACIAL PREDILECTION OF 
HIVAN
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             Percentage of total biopsies  Percentage of total biopsies
Histological lesion on renal biopsy            (King Edward study)  (Chris Hani Baragwanath study)
HIVAN                70%  27%
HIV-IC                -  21%
Membranous nephropathy               13.3% (all with HIVAN)  13%
Other non-glomerulonephritic renal diseases            -  10%
Other glomerulonephritides               -    9%
Post-infectious glomerulonephritis               -    8%
Mesangioproliferative glomerulonephritis               -    6%
IgA nephropathy                -    5%
Membranoproliferative glomerulonephritis               6.6%    -
Interstitial nephritis                10.1%    -
TABLE IV. HIV-INFECTED PATIENTS BIOPSIED IN SOUTH AFRICA20, 21
ART  Triple therapy: dose adjusted for renal failure
  (see Table VI)
ACE-I or A2RB   If proteinuria >1 g/24 hours or if proteinuria on diptsick persists 
  after 3 months on ART
Corticosteroids  After consultation with a nephrologist
Chronic renal failure  Refer to a nephrologist if possible, manage as for any patient with
(follow up 3-monthly)  chronic renal failure:
     Hypertension (aim for BP <120/70 mmHg)
     Calcium/phosphate/potassium metabolism
     Anaemia (especially if using AZT/3TC)
     Acidosis
     Dyslipidaemia 
     Dietary recommendations
End-stage renal disease Initiate renal replacement therapy or refer to nephrologist if 
  therapy unavailable
TABLE V. CURRENT RECOMMENDATIONS FOR MANAGEMENT OF HIVAN
Agent  Normal dose Estimated GFR (creatinine clearance: Cr Cl)
Zidovudine  300 mg bd po 10 - 50 ml/min = 200 mg tds
   <10 ml/min = 100 mg tds po
Lamivudine  150 mg bd po 30 - 49 ml/min = 150 mg daily po
   15 - 29 ml/min = 100 mg daily po
   5 - 14 ml/min  = 50 mg daily po
   <5 ml/min = 25 mg daily po
Stavudine  30 mg bd po 26 - 50 ml/min = 15 mg bd po
   <26 ml/min = 15 mg daily po
Didanosine  >60 kg: 200 mg bd po 30 - 59 ml/min = 200 mg daily po
   10 - 29 ml/min = 150 mg daily po
   <10 ml/min  = 100 mg daily po
  <60 kg 30 - 59 ml/min = 150 mg daily po
  125 mg bd po 10 - 29 ml/min = 100 mg daily po
   <10 ml/min   = 75 mg daily po
Tenofovir  300 mg daily po 30 - 49 ml/min = 300 mg every second day
   10 - 29 ml/min = 300 mg every third day
   <10 ml/min  = 300 mg once-weekly
*No dose adjustment necessary for abacavir; protease inhibitors, nevirapine, delavirine and efavirenz are all metabolised by liver and dose adjustment is not indicated.
TABLE VI.  DOSE ADJUSTMENT FOR COMMONLY-USED NNRTI*
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unexplained. Some have postulated a genetic predisposition, 
but candidate genes have not been identified.14,39 Studies 
involving the HIV transgenic mouse, bearing the gag-pol-
deleted HIV transgene, have provided valuable insight 
into the genetic determinants of renal disease. This strain 
of mouse develops renal disease very similar to HIVAN in 
humans, but when these mice are bred onto various other 
genetic backgrounds, the phenotypic expression of renal 
disease differs greatly.3 One study has shown that there 
appears to be a strong familial clustering of ESRD among 
blacks commencing renal replacement therapy due to 
HIVAN.41 This clustering appears to be independent of HIV 
infection per se. In most cases, the affected relatives had 
ESRD due to hypertension or diabetes. HIVAN also appears 
to follow a more severe clinical course in black patients.42 
Studies in black patients have shown a higher prevalence 
of both severe glomerular lesions (focal glomerulosclerosis) 
and nephrotic-range proteinuria with renal dysfunction in 
the presence of normo-hypotension.1,40,42
In the 1980s, HIVAN was an uncommon cause of ESRD in 
the USA.43 This was partly due to the high mortality in this 
group and the absence of ART. With improved survival after 
the introduction of ART, HIVAN became the most rapidly 
increasing cause of ESRD in the USA by 1990.43 In 1995, 
although the decline in mortality from AIDS was dramatic, 
the number of new cases of ESRD due to HIVAN did not 
decline.43 Instead, mortality data have shown a steady 
plateau in the Afro-American population, the population at 
highest risk for HIVAN in the USA.43-45 In 2004, HIVAN was 
the seventh leading cause of ESRD in Afro-Americans.
Statistics in the USA estimate the incidence of HIVAN to be 
3.5 - 12%.43 If this were extrapolated to sub-Saharan Africa 
(with an estimated 25.8 million people infected with HIV), 
between 903 000 and 3.1 million people would be predicted 
to have HIVAN. With the advent of unrestricted access to 
ART, one may postulate that the epidemiological pattern 
of HIVAN that evolved in the USA over the last 14 years 
may predict what will happen in sub-Saharan Africa. This 
presents a potentially unprecedented burden of chronic 
kidney disease, given the current resources available for 
managing renal disease in this region. There is a critical role 
for local research, in the form of prospective randomised 
controlled trials on the impact of early diagnosis and 
treatment of HIVAN and its effect on outcome regarding 
morbidity, mortality, and prevention of progression to ESRD 
in sub-Saharan Africa. In addition, a national programme 
needs to be devised on the comprehensive management of 
renal disease in HIV-1 infection that addresses not only the 
prevention of renal disease but also the management of 
those with CKD, including renal replacement therapy and 
transplantation.
HIVAN is characterised by a specific constellation of 
pathological findings on biopsy that involve glomerular, 
tubular and interstitial compartments of the kidney 
(Fig. 1).1,31,46
The management of biopsy-proven HIVAN involves not 
only ART but, in those with chronic renal failure, also the 
same treatment that would apply for any patient with 
the condition. This includes referral to a nephrologist, if 
possible; regular follow-up; monitoring and treatment of 
blood pressure, potassium, calcium, phosphate and lipid 
metabolism; anaemia management; and appropriate dose 
adjustment for nephrotoxic agents including ART. In those 
who progress to end-stage renal failure, the initiation 
of renal replacement therapy – which includes dialysis 
(haemo/peritoneal) and renal transplantation – needs to be 
initiated timeously and appropriately. There have been no 
prospective randomised controlled studies with any form of 
therapy for HIVAN to date. Therapies used in the treatment 
of HIVAN include corticosteroids, angiotensin-converting 
enzyme inhibitors (ACE-I) and ART.
Corticosteroids
In various studies, patients with HIVAN treated with 
prednisone experienced an improvement in renal function 
and reduction of proteinuria, but complications such as 
relapse after steroid withdrawal, opportunistic infections, 
psychosis and gastrointestinal bleeding were relatively 
common.47,48 The use of corticosteroids has become less 
important since the advent of ART and ACE-I treatment. 
The role for corticosteroids should be reserved for 
refractory cases of severe nephrotic syndrome already on 
ART and ACE-I and be administered after consultation with 
a nephrologist.
Angiotensin-converting enzyme inhibitors (ACE-Is)
Different ACE-Is (captopril; fosinopril) have been shown 
to reduce proteinuria, stabilise renal function and delay 
the progression of renal failure in HIVAN. Some of these 
studies were conducted prior to the availability of ART. 
The potentially beneficial effects of ACE-I may be related 
HISTOPATHOLOGY OF HIVAN
MANAGEMENT OF HIVAN
Fig. 1. Typical histopathological findings of HIVAN.46 
Periodic acid-Schiff staining demonstrates focal segmental 
glomerulosclerosis (arrowhead) with collapse of the 
glomerular tuft (arrow), tubular microcystic disease (*), 
interstitial lymphocytic infiltration and interstitial fibrosis. 
Magnification ×200.
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to improved renal haemodynamic, reduced proteinuria 
or cytokine modulation (Infectious Diseases Society of 
America) (IDSA). The effects of ARB (angiotensin-2 receptor 
blockers) in the treatment of HIVAN are unknown, just 
as the effects of ACE-I or ARB in the treatment of HIV-
associated renal disease other than HIVAN are unknown.
Highly active antiretroviral therapy (HAART)
Because HIV-1 itself appears to be the cause of HIVAN and 
may contribute to other renal diseases in HIV-1-infected 
patients (e.g. immune-complex glomerulonephritides), 
ART appears to be a logical choice in the management 
of HIV-associated renal disease. Initially, zidovudine (AZT) 
monotherapy was shown to be beneficial in the treatment 
of HIVAN.49,50 There appears to be a more beneficial effect 
of ART (triple combination) over zidovudine monotherapy 
in the management of HIVAN.25-28,51 In addition to being 
effective in treating established HIVAN, ART may decrease 
the actual incidence of de novo HIVAN.52,53
Renal disease in HIV infection is common, multifactorial 
and often challenging – for patient and clinician. If 
untreated or inappropriately managed, it can be fatal. It is 
not only essential for clinicians to be able to manage renal 
disease in HIV but also for them to be able to access referral 
institutions and nephrologists for support.
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